This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medtronic's (MDT) Study Shows Positive Results of TDD Use (revised)
by Zacks Equity Research
The outcomes of the study demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Will Instruments Drive Intuitive Surgical (ISRG) Q1 Earnings?
by Zacks Equity Research
Intuitive Surgical's (ISRG) Systems and Services revenues are likely to boost Q1 results.
Top Analyst Reports for Bank of America, Amgen & NextEra Energy
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bank of America (BAC), Amgen (AMGN) and NextEra Energy (NEE).
ResMed's Brightree Widens ReSupply Solution Usage for HME
by Zacks Equity Research
Resmed's (RMD) Brightree ReSupply is a scalable and automated solution that comprises live-agent inbound and outbound calls for more private interaction with patients and email reminder capabilities.
Here's Why Investors Should Retain Accuray (ARAY) Stock Now
by Zacks Equity Research
Management at Accuray (ARAY) sees significant opportunities in China.
Walgreens Partners With VillageMD to Offer Primary Healthcare
by Zacks Equity Research
This joint venture marks Walgreens' (WBA) commitment toward enabling access to affordable healthcare and creating neighborhood health destinations.
Medtronic's (MDT) Study Shows Positive Results of TDD Use
by Zacks Equity Research
The outcomes of the study, conducted by Medtronic (MDT), demonstrates that patients on TDD along with CMM witnessed some major benefits compared to those on CMM alone.
Here's Why You Should Buy Varian Medical (VAR) Stock Now
by Zacks Equity Research
Varian Medical (VAR) announces the installation of cyclotron for its ProBeam proton therapy system at the Hefei Ion Medical Center in China.
Walgreens' Weak Market Trends a Woe, Strategic Deals to Aid
by Zacks Equity Research
Walgreens Boots (WBA) currently endeavors to redress certain areas of operational weakness and reinforces its managerial competence to drive operating efficiency with a resolute focus.
Medtronic (MDT) Inks Value-Based Deal for Guardian Connect
by Zacks Equity Research
Medtronic's (MDT) Guardian Connect system can now be accessed via a Blue Cross and Blue Shield of Minnesota member's pharmacy benefit.
Varian Medical's (VAR) ProBeam Installed in China's HIMC
by Zacks Equity Research
Varian Medical (VAR) has seen some notable developments in its Proton Therapy business in recent times.
Bio-Rad's (BIO) IH-500 System Secures 510(K) From the FDA
by Zacks Equity Research
The regulatory go-ahead is in line with Bio-Rad's (BIO) strategy of strengthening in the transfusion medicine market of the United States.
Intersect ENT Grows on Product Launch Amid Pricing Pressure
by Zacks Equity Research
Intersect ENT (XENT) recently finishes the ENCORE Study, which is a small 50-patient open label program, designed to evaluate the safety of the repeat use of SINUVA.
Natus Medical to Divest Medix for Focusing on Core Business
by Zacks Equity Research
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
5 ROE Stocks to Buy on Solid Jobs Data & Trade Deal Odds
by Supriyo Bose
ROE helps investors distinguish profit-generating companies from profit burners and is useful in determining the financial health of a company.
Orthofix (OFIX) Reports Encouraging M6-C Disc Study Results
by Zacks Equity Research
The primary goal of the study was to assess the safety and efficacy of Orthofix's (OFX) M6-C artificial cervical disc in comparison to ACDF treatment.
ResMed's (RMD) Brightree Unveils Analytics Platform for HME
by Zacks Equity Research
The Analytics arm, launched by ResMed (RMD) unit Brightree, provides workflow insights and facilitates KPI tracking plus peer benchmarking without the users having to amass the data themselves.
LabCorp (LH)-QIAGEN Form Alliance in In-Vitro Diagnostics
by Zacks Equity Research
LabCorp's (LH) wide exposure in the companion diagnostics space further enhances QIAGEN's personalized health collaborations with the pharmaceutical bigwigs.
ResMed (RMD) Rides on International Growth & Innovation
by Zacks Equity Research
We expect ResMed's (RMD) new product menu and strategies to gain traction from the sleep-disordered breathing market and further drive its near-term performance.
Inogen (INGN) Launches One G5 Portable Oxygen Concentrator
by Zacks Equity Research
Inogen's (INGN) product launch is in line with the company's strategy of providing innovative and long-term oxygen therapy to patients in need of respiratory aid.
Integra's Product Launch a Growth Catalyst, Rivalry Rife
by Zacks Equity Research
Product launches and a sales force performance upgrade are likely to boost rapid organic growth for Integra LifeSciences (IART) in the second half of 2019.
Can Stryker (SYK) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Stryker (SYK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Varian Announces Halcyon's First Successful Case in Malaysia
by Zacks Equity Research
Varian's (VAR) Halcyon is much superior to traditional technologies, thanks to the speed of treatment and improved quality of patient care it offers.
NuVasive (NUVA) Completes First COHERE XLIF Case in U.S.
by Zacks Equity Research
NuVasive's (NUVA) Advanced Materials Science implant portfolio will be fortified by the incorporation of the Porous PEEK technology into its implants for lateral single-position surgery.
Medtronic's Diabetes Arm Grows Strong, Rising Costs Ail
by Zacks Equity Research
Medtronic (MDT) is highly optimistic about its foray into the $1-billion standalone CGM market with its Guardian Connect.